Thyroid Dysfunction from Treatments for Solid Organ Cancers

• Autores: Anupam Kotwal, Donald S.A. McLeod
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 51, Nº. 2, 2022, págs. 265-286
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Immune checkpoint inhibitors frequently cause thyroiditis mostly as hypothyroidism, either at presentation or preceded by a thyrotoxic phase. Thyroiditis from immune checkpoint inhibitors appears to be T lymphocyte mediated but requires further investigation. Kinase inhibitors may cause direct thyroid dysfunction from vascular injury or increase in levothyroxine metabolism. The high prevalence of thyroid dysfunction after I-131-metaiodobenzylguanidine despite iodine prophylaxis highlights the need for better risk prediction and prophylactic regimens. There appears to be a survival advantage of thyroid dysfunction from immune checkpoint and kinase inhibitors that supports their role as a potential marker for therapeutic efficacy against the malignancy